Philippe Ronga Md-Independent Medical Affairs & Clinical Development Consultant

Nexevan Advisory provides independent senior clinical and AI strategy support to PE/VC funds, Boards, and Leadership teams investing in or scaling clinically complex Healthcare businesses.

I support clients across pre-investment diligence, portfolio value creation, evidence and adoption strategy, cross-border growth, AI Governance, strategic-buyer readiness, and Board advisory.

The advisory scope spans BioPharma, MedTech, HealthTech, Diagnostics, and specialty Healthcare services, supported by deep expertise in Oncology, Haematology, Rare Diseases, and Internal Medicine.

Engagements include 7-14-day red-flag reviews, 2-6-week strategic deep dives, project-based mandates, Board and strategic advisory retainers, and fractional executive support.

→ MEDICAL EXCELLENCE: OVERSAW GLOBAL MEDICAL AFFAIRS DECISION BOARD, DATA MAPPING, & LIFE CYCLE MANAGEMENT

• Structured Global Medical Affairs approach for meaningful studies, research impact, and global medical decision alignment.
• Chaired Global Medical Affairs Decision Board (Legal, Regulatory, Clinical Development, Statistician, HEOR, and other Leaders) to streamline approvals.
• Directed Data Generation, Life Cycle Management, Phase IV study coordination, Advisory Board meetings, and materials creation for MSLs.
• Led Medical Affairs, Marketing, Market Access / HEOR, and Commercial country leaders in new drug combination launch preparation.
• Maintained engagement among Healthcare and Patient Advocacy Groups.

→ LIFE CYCLE TRENDS, REAL-WORLD DATA, & GLOBAL MEDICAL DECISION ALIGNMENT ACHIEVEMENTS

• Identified Life Cycle Management trends by mapping data from ISTs; optimized IST strategy and generated valuable data in BRAF-mt.
• Worked with In-Vitro Diagnostics companies to provide Liquid Biopsy test for key decisions in Life Cycle Management.
• Organized ACTivate GI Ad Board meetings, including virtual communications platforms.
• Partnered with Regulatory Affairs to represent Medical Affairs on drug labelling documentation.
• Illuminated Real-World Data discoveries from Insurance claims database, with findings presented in specialist journal and congresses (HEOR).
• Produced new insights by examining indication role in neuropathic pain (Proof-of-Concept, Clinical Development), working with investigators.

→ MEDICAL EXCELLENCE, STRATEGIC MEDICAL AFFAIRS PLANNING, M&A INTEGRATION, & COUNTRY AFFILIATE OVERSIGHT

• Managed European Phase IV program in metastatic Breast Cancer and Supportive Care, leading cross-functional team including CROs, Drug Safety, Biostatistics, and Medical Writing leaders, line management reports, and 27 dotted-line country reports; developed budgets.
• Organized European Advisory Boards and Congress Satellite Symposia.
• Administered Medical Affairs for Oncology and Hematologic Malignancies, Biologics, and Biosimilars; produced and executed strategic Medical Affairs plan.

→ EUROPEAN LAUNCH READINESS & POST-M&A TEAM & PROGRAM INTEGRATION ACHIEVEMENTS

• Coordinated medical launch preparation for new oncology supportive care product, ensuring medical support and alignment among cross-functional teams (Market Access, Legal, Regulatory, Clinical Development, other Leaders) and aggressive timelines.
• Preserved productivity and strong morale by leading team members through acquisition and restructuring.
• Cultivated and managed European KOL network; organized European Advisory Boards and Congress Satellite Symposia, including agendas and speaker selection.

→ CLINICAL RESEARCH, MULTIPLE IST LAUNCHES, & SALES FORCE MEDICAL TRAINING

• Drove 6 IST launches by heading Clinical Research, implementing company-sponsored Phase III study (Clinical Development), and managing French Phase I and II ISTs.
• Built and managed French Key Opinion Leader relationships.
• Led first Genzyme French Chronic Lymphocytic Leukaemia Advisory Board; organized local symposia.
• Led Sales Force Medical Training with Marketing team; facilitated onboarding.

→ IMPLEMENTATION FOR COMPANY SPONSORED PHASE III CLINICAL RESEARCH STUDIES

• Engaged, developed, and managed Swiss KOL network, supporting research studies (Clinical Development) for Type II Diabetes, Hypertension, Osteoarthritis and Osteoporosis.
• Led Sales Team training with Marketing Team; facilitated new collaborator onboarding.